Drug class
Non-replicating adenoviral vector gene therapy delivering interferon alfa-2b
Mechanism of action
An adenoviral vector delivers the human IFNα2b gene to bladder urothelial cells. Transduced cells express interferon alfa-2b locally, promoting antitumour immune responses and growth-inhibitory effects within the bladder.
General use cases
- Treatment of adults with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumours; for intravesical use only
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
